Eintrag weiter verarbeiten
Online-Ressource

Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: The Journal of Clinical Hypertension
Personen und Körperschaften: Zhang, Ling, Sun, Xiuting, Liao, Lizhen, Zhang, Shaozhao, Zhou, Huimin, Zhong, Xiangbin, Zhuang, Xiaodong, Liao, Xinxue
In: The Journal of Clinical Hypertension, 21, 2019, 12, S. 1813-1820
Format: E-Article
Sprache: Englisch
veröffentlicht:
Wiley
Schlagwörter:
Cardiology and Cardiovascular Medicine
Endocrinology, Diabetes and Metabolism
Internal Medicine
author_facet Zhang, Ling
Sun, Xiuting
Liao, Lizhen
Zhang, Shaozhao
Zhou, Huimin
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
Zhang, Ling
Sun, Xiuting
Liao, Lizhen
Zhang, Shaozhao
Zhou, Huimin
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
author Zhang, Ling
Sun, Xiuting
Liao, Lizhen
Zhang, Shaozhao
Zhou, Huimin
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
spellingShingle Zhang, Ling
Sun, Xiuting
Liao, Lizhen
Zhang, Shaozhao
Zhou, Huimin
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
The Journal of Clinical Hypertension
Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
Cardiology and Cardiovascular Medicine
Endocrinology, Diabetes and Metabolism
Internal Medicine
author_sort zhang, ling
spelling Zhang, Ling Sun, Xiuting Liao, Lizhen Zhang, Shaozhao Zhou, Huimin Zhong, Xiangbin Zhuang, Xiaodong Liao, Xinxue 1524-6175 1751-7176 Wiley Cardiology and Cardiovascular Medicine Endocrinology, Diabetes and Metabolism Internal Medicine http://dx.doi.org/10.1111/jch.13720 <jats:title>Abstract</jats:title><jats:p>This was a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT), aimed to investigate whether intensive blood pressure treatment has differential therapeutic outcomes on patients with different baseline Framingham risk score (FRS). The 9298 SPRINT participants were categorized into low‐risk (baseline FRS &lt; 10%), intermediate‐risk (FRS = 10%‐20%), or high‐risk (FRS &gt; 20%) arms. The primary outcome was a composite of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Serious adverse events were defined as hypotension, syncope, and bradycardia. Multiple Cox regression was used to calculate hazard ratios for study outcomes with intensive compared with standard SBP treatment between these three groups. After a median follow‐up time of 3.26 years, the primary outcome hazard ratio (HR) for intensive versus standard treatment was 0.73 (95% CI: 0.61‐0.88, <jats:italic>P</jats:italic> = .0044) in the high‐risk arm. And, for all‐cause mortality, the hazard ratio with intensive SBP treatment was 1.58 (95% CI: 0.55‐1.06), 0.9 (95% CI: 0.26‐9.50), and 0.53 (95% CI: 0.34‐0.82) in three arms (all <jats:italic>P</jats:italic> values for interaction &gt; 0.05). Effects of intensive versus standard SBP control on serious adverse events were similar among patients with different FRS. Our results suggested that regardless of the FRS level, the intensive blood pressure control was beneficial.</jats:p> Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) The Journal of Clinical Hypertension
doi_str_mv 10.1111/jch.13720
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qY2guMTM3MjA
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qY2guMTM3MjA
institution DE-D161
DE-Zwi2
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
imprint Wiley, 2019
imprint_str_mv Wiley, 2019
issn 1751-7176
1524-6175
issn_str_mv 1751-7176
1524-6175
language English
mega_collection Wiley (CrossRef)
match_str zhang2019effectivenessofbloodpressureloweringtreatmentbythelevelsofbaselineframinghamriskscoreaposthocanalysisofthesystolicbloodpressureinterventiontrialsprint
publishDateSort 2019
publisher Wiley
recordtype ai
record_format ai
series The Journal of Clinical Hypertension
source_id 49
title Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_unstemmed Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_full Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_fullStr Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_full_unstemmed Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_short Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_sort effectiveness of blood pressure–lowering treatment by the levels of baseline framingham risk score: a post hoc analysis of the systolic blood pressure intervention trial (sprint)
topic Cardiology and Cardiovascular Medicine
Endocrinology, Diabetes and Metabolism
Internal Medicine
url http://dx.doi.org/10.1111/jch.13720
publishDate 2019
physical 1813-1820
description <jats:title>Abstract</jats:title><jats:p>This was a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT), aimed to investigate whether intensive blood pressure treatment has differential therapeutic outcomes on patients with different baseline Framingham risk score (FRS). The 9298 SPRINT participants were categorized into low‐risk (baseline FRS &lt; 10%), intermediate‐risk (FRS = 10%‐20%), or high‐risk (FRS &gt; 20%) arms. The primary outcome was a composite of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Serious adverse events were defined as hypotension, syncope, and bradycardia. Multiple Cox regression was used to calculate hazard ratios for study outcomes with intensive compared with standard SBP treatment between these three groups. After a median follow‐up time of 3.26 years, the primary outcome hazard ratio (HR) for intensive versus standard treatment was 0.73 (95% CI: 0.61‐0.88, <jats:italic>P</jats:italic> = .0044) in the high‐risk arm. And, for all‐cause mortality, the hazard ratio with intensive SBP treatment was 1.58 (95% CI: 0.55‐1.06), 0.9 (95% CI: 0.26‐9.50), and 0.53 (95% CI: 0.34‐0.82) in three arms (all <jats:italic>P</jats:italic> values for interaction &gt; 0.05). Effects of intensive versus standard SBP control on serious adverse events were similar among patients with different FRS. Our results suggested that regardless of the FRS level, the intensive blood pressure control was beneficial.</jats:p>
container_issue 12
container_start_page 1813
container_title The Journal of Clinical Hypertension
container_volume 21
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792348037544149001
geogr_code not assigned
last_indexed 2024-03-01T18:04:48.141Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Effectiveness+of+blood+pressure%E2%80%93lowering+treatment+by+the+levels+of+baseline+Framingham+risk+score%3A+A+post+hoc+analysis+of+the+Systolic+Blood+Pressure+Intervention+Trial+%28SPRINT%29&rft.date=2019-12-01&genre=article&issn=1751-7176&volume=21&issue=12&spage=1813&epage=1820&pages=1813-1820&jtitle=The+Journal+of+Clinical+Hypertension&atitle=Effectiveness+of+blood+pressure%E2%80%93lowering+treatment+by+the+levels+of+baseline+Framingham+risk+score%3A+A+post+hoc+analysis+of+the+Systolic+Blood+Pressure+Intervention+Trial+%28SPRINT%29&aulast=Liao&aufirst=Xinxue&rft_id=info%3Adoi%2F10.1111%2Fjch.13720&rft.language%5B0%5D=eng
SOLR
_version_ 1792348037544149001
author Zhang, Ling, Sun, Xiuting, Liao, Lizhen, Zhang, Shaozhao, Zhou, Huimin, Zhong, Xiangbin, Zhuang, Xiaodong, Liao, Xinxue
author_facet Zhang, Ling, Sun, Xiuting, Liao, Lizhen, Zhang, Shaozhao, Zhou, Huimin, Zhong, Xiangbin, Zhuang, Xiaodong, Liao, Xinxue, Zhang, Ling, Sun, Xiuting, Liao, Lizhen, Zhang, Shaozhao, Zhou, Huimin, Zhong, Xiangbin, Zhuang, Xiaodong, Liao, Xinxue
author_sort zhang, ling
container_issue 12
container_start_page 1813
container_title The Journal of Clinical Hypertension
container_volume 21
description <jats:title>Abstract</jats:title><jats:p>This was a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT), aimed to investigate whether intensive blood pressure treatment has differential therapeutic outcomes on patients with different baseline Framingham risk score (FRS). The 9298 SPRINT participants were categorized into low‐risk (baseline FRS &lt; 10%), intermediate‐risk (FRS = 10%‐20%), or high‐risk (FRS &gt; 20%) arms. The primary outcome was a composite of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Serious adverse events were defined as hypotension, syncope, and bradycardia. Multiple Cox regression was used to calculate hazard ratios for study outcomes with intensive compared with standard SBP treatment between these three groups. After a median follow‐up time of 3.26 years, the primary outcome hazard ratio (HR) for intensive versus standard treatment was 0.73 (95% CI: 0.61‐0.88, <jats:italic>P</jats:italic> = .0044) in the high‐risk arm. And, for all‐cause mortality, the hazard ratio with intensive SBP treatment was 1.58 (95% CI: 0.55‐1.06), 0.9 (95% CI: 0.26‐9.50), and 0.53 (95% CI: 0.34‐0.82) in three arms (all <jats:italic>P</jats:italic> values for interaction &gt; 0.05). Effects of intensive versus standard SBP control on serious adverse events were similar among patients with different FRS. Our results suggested that regardless of the FRS level, the intensive blood pressure control was beneficial.</jats:p>
doi_str_mv 10.1111/jch.13720
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qY2guMTM3MjA
imprint Wiley, 2019
imprint_str_mv Wiley, 2019
institution DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1
issn 1751-7176, 1524-6175
issn_str_mv 1751-7176, 1524-6175
language English
last_indexed 2024-03-01T18:04:48.141Z
match_str zhang2019effectivenessofbloodpressureloweringtreatmentbythelevelsofbaselineframinghamriskscoreaposthocanalysisofthesystolicbloodpressureinterventiontrialsprint
mega_collection Wiley (CrossRef)
physical 1813-1820
publishDate 2019
publishDateSort 2019
publisher Wiley
record_format ai
recordtype ai
series The Journal of Clinical Hypertension
source_id 49
spelling Zhang, Ling Sun, Xiuting Liao, Lizhen Zhang, Shaozhao Zhou, Huimin Zhong, Xiangbin Zhuang, Xiaodong Liao, Xinxue 1524-6175 1751-7176 Wiley Cardiology and Cardiovascular Medicine Endocrinology, Diabetes and Metabolism Internal Medicine http://dx.doi.org/10.1111/jch.13720 <jats:title>Abstract</jats:title><jats:p>This was a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT), aimed to investigate whether intensive blood pressure treatment has differential therapeutic outcomes on patients with different baseline Framingham risk score (FRS). The 9298 SPRINT participants were categorized into low‐risk (baseline FRS &lt; 10%), intermediate‐risk (FRS = 10%‐20%), or high‐risk (FRS &gt; 20%) arms. The primary outcome was a composite of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Serious adverse events were defined as hypotension, syncope, and bradycardia. Multiple Cox regression was used to calculate hazard ratios for study outcomes with intensive compared with standard SBP treatment between these three groups. After a median follow‐up time of 3.26 years, the primary outcome hazard ratio (HR) for intensive versus standard treatment was 0.73 (95% CI: 0.61‐0.88, <jats:italic>P</jats:italic> = .0044) in the high‐risk arm. And, for all‐cause mortality, the hazard ratio with intensive SBP treatment was 1.58 (95% CI: 0.55‐1.06), 0.9 (95% CI: 0.26‐9.50), and 0.53 (95% CI: 0.34‐0.82) in three arms (all <jats:italic>P</jats:italic> values for interaction &gt; 0.05). Effects of intensive versus standard SBP control on serious adverse events were similar among patients with different FRS. Our results suggested that regardless of the FRS level, the intensive blood pressure control was beneficial.</jats:p> Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) The Journal of Clinical Hypertension
spellingShingle Zhang, Ling, Sun, Xiuting, Liao, Lizhen, Zhang, Shaozhao, Zhou, Huimin, Zhong, Xiangbin, Zhuang, Xiaodong, Liao, Xinxue, The Journal of Clinical Hypertension, Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine
title Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_full Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_fullStr Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_full_unstemmed Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_short Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
title_sort effectiveness of blood pressure–lowering treatment by the levels of baseline framingham risk score: a post hoc analysis of the systolic blood pressure intervention trial (sprint)
title_unstemmed Effectiveness of blood pressure–lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
topic Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine
url http://dx.doi.org/10.1111/jch.13720